Identification
- Summary
Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
- Brand Names
- Siliq
- Generic Name
- Brodalumab
- DrugBank Accession Number
- DB11776
- Background
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Brodalumab
- External IDs
- AMG 827
- AMG-827
- KHK-4827
- KHK4827
Pharmacology
- Indication
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Severe plaque psoriasis •••••••••••• ••••• Treatment of Moderate plaque psoriasis •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Increase in the level of IL-17 due to blocking of its receptors.
- Mechanism of action
Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.
- Absorption
Not Available
- Volume of distribution
4.62 L.
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
0.223 L/day.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Brodalumab. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Brodalumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Brodalumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brodalumab. Aducanumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Aducanumab. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Kyntheum Injection, solution 210 mg Subcutaneous Leo Pharma 2020-12-22 Not applicable EU 
Kyntheum Injection, solution 210 mg Subcutaneous Leo Pharma 2020-12-22 Not applicable EU Siliq Solution 210 mg / 1.5 mL Subcutaneous Bausch Health, Canada Inc. 2018-07-05 Not applicable Canada 
Siliq Injection 210 mg/1 Subcutaneous Bausch Health US LLC 2017-02-15 Not applicable US 
Categories
- ATC Codes
- L04AC12 — Brodalumab
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antineoplastic and Immunomodulating Agents
- Blood Proteins
- Dermatologicals
- Globulins
- Immunoglobulins
- Immunoproteins
- Immunosuppressive Agents
- Interleukin 17 Receptor A Antagonists
- Interleukin Inhibitors
- Interleukin-17 Receptor A Antagonist
- Proteins
- Receptors, Interleukin-17
- Serum Globulins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 6ZA31Y954Z
- CAS number
- 1174395-19-7
References
- General References
- External Links
- KEGG Drug
- D10061
- PubChem Substance
- 347911240
- 1872251
- Wikipedia
- Brodalumab
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Psoriasis / Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Completed Treatment Psoriasis 1 4 Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) 1 4 Completed Treatment Psoriasis Vulgaris (Plaque Psoriasis) / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular; Psoriasis, Palmaris Et Plantaris 1 4 Recruiting Treatment Psoriasis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Parenteral; Subcutaneous 210 MG Injection, solution Subcutaneous 210 mg Injection Parenteral Injection, solution Subcutaneous 210 mg/1.5mL Injection Subcutaneous 210 mg/1 Solution Subcutaneous 210 mg / 1.5 mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 20, 2016 20:47 / Updated at June 03, 2022 07:24